Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for Difficult-to-Treat depression

@article{Manji2003EnhancingNP,
  title={Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for Difficult-to-Treat depression},
  author={Husseini K. Manji and Jorge A. Quiroz and Jonathan R. Sporn and Jennifer L. Payne and Kirk K Denicoff and Neil Gray and Carlos A. Zarate and Dennis S. Charney},
  journal={Biological Psychiatry},
  year={2003},
  volume={53},
  pages={707-742}
}
There is growing evidence from neuroimaging and ostmortem studies that severe mood disorders, which have traditionally been conceptualized as neurochemical disorders, are associated with impairments of structural plasticity and cellular resilience. It is thus noteworthy that recent preclinical studies have shown that critical molecules in neurotrophic signaling cascades (most notably cyclic adenosine monophosphate [cAMP] response element binding protein, brain-derived neurotrophic factor, bcl-2… Expand
Glutamate modulators as novel interventions for mood disorders.
TLDR
A focused review of the extant scientific literature was conducted, with a discussion of 3 compounds or classes of drugs currently undergoing clinical investigation: ketamine, riluzole, and AMPA receptor potentiators. Expand
Cellular Plasticity Cascades: Targets for the Development of Novel Therapeutics for Bipolar Disorder
TLDR
Effective treatments for bipolar disorder will need to provide both trophic and neurochemical support, which serves to enhance and maintain normal synaptic connectivity, thereby allowing the chemical signal to reinstate the optimal functioning of critical circuits necessary for normal affective functioning. Expand
Neural circuitry and neuroplasticity in mood disorders: Insights for novel therapeutic targets
TLDR
Modulation of dysregulated activity in these affective circuits via pharmacological agents that enhance neuronal resilience and plasticity, and possibly via emerging nonpharmacologic, circuitry-based modalities offers promising targets for novel experimental therapeutics in the treatment of mood disorders. Expand
Neurotrophic signaling cascades are major long-term targets for lithium: clinical implications
Abstract Although mood disorders have traditionally been regarded as good prognosis diseases, a growing body of data suggests that the long-term outcome for many patients is often much less favorableExpand
Regulation of cellular plasticity and resilience by mood stabilizers: the role of AMPA receptor trafficking
TLDR
Regulation of glutamatergically mediated synaptic plasticity may play a role in the treatment of mood disorders, and raises the possibility that agents more directly affecting synaptic GluR1 represent novel therapies for these devastating illnesses. Expand
Preclinical approaches to examine novel concepts of the pathophysiology of depressive disorders: lessons learned from tree shrews
Recent studies have provided evidence that mood disorders such as major depression not only have a neurochemical basis but are also associated with alterations in neuronal and glial structures.Expand
Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders.
TLDR
The most recent findings regarding the potential targets involved in lithium's neuroprotective effects are reviewed, and the implication of these findings for the treatment of a variety of diseases is reviewed. Expand
State of the art of the neurotrophin hypothesis in psychiatric disorders: implications and limitations
TLDR
The issue of neuroprotection and neurotrophins is recognised as an important new lead in the quest for a deeper understanding of psychiatric disorders and the mechanisms of action of psychopharmacological interventions. Expand
Novel insights into depression and antidepressants: a synergy between synaptogenesis and neurogenesis?
TLDR
The ways by which improving both neurogenesis and synaptogenesis may enable effective recovery by acting on a larger neuronal network are described. Expand
Evaluation of the Wistar-Kyoto rat model of depression and the role of synaptic plasticity in depression and antidepressant response
TLDR
This review focuses on the available literature supporting the Wistar-Kyoto rat as a model of endogenous stress susceptibility and depression, and the role of synaptic plasticity in depression and antidepressant response in the context of this model. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 289 REFERENCES
Enhancing synaptic plasticity and cellular resilience to develop novel, improved treatments for mood disorders
TLDR
Preclinical and clinical data suggest that attenuation of N-methyl-D-aspartate (NMDA) function has antidepressant effects and there is much promise for the future development of treatments that more directly target molecules in critical CNS signaling pathways regulating synaptic plasticity and cellular resilience. Expand
Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics.
TLDR
Evidence from a variety of sources demonstrating regional reductions in central nervous system volume, as well as reductions in the numbers and/or sizes of glia and neurons in discrete brain areas suggests that mood disorders are associated with impairments of structural plasticity and cellular resilience. Expand
Neuroplasticity and cellular resilience in mood disorders
TLDR
It is proposed that impairments of neuroplasticity and cellular resilience may underlie the pathophysiology of mood disorders, and further that optimal long-term treatment for these severe illnesses may only be achieved by the early and aggressive use of agents with neurotrophic/ neuroprotective effects. Expand
Neuroprotective effects of antidepressant and mood stabilizing drugs.
  • L. Young
  • Medicine, Psychology
  • Journal of psychiatry & neuroscience : JPN
  • 2002
TLDR
Animal studies suggest that antidepressant and mood stabilizing drugs are neuroprotective and may also lead to neurogenesis in selected brain regions, and additional evidence obtained from the examination of brain tissue of patients with mood disorders supports the proposed targets of these drugs. Expand
Antidepressants and neuroplasticity.
TLDR
The results suggest that depression maybe associated with a disruption of mechanisms that govern cell survival and neural plasticity in the brain and antidepressants could mediate their effects by increasing neurogenesis and modulating the signaling pathways involved in plasticity and survival. Expand
Modulators of the glutamatergic system: implications for the development of improved therapeutics in mood disorders.
TLDR
This article reviews the growing body of data suggesting that agents which modulate the glutamatergic system may have utility in the long-term treatment of severe, recurrent mood disorders and suggests that a-amino-3-hydroxy-5-methylisoxazole-4-propionic acid potentiators should be considered. Expand
Anti-bipolar therapy: mechanism of action of lithium
  • R. Jope
  • Biology, Medicine
  • Molecular Psychiatry
  • 1999
This review introduces the concepts that multiple actions of lithium are critical for its therapeutic effect, and that these complex effects stabilize neuronal activities, support neural plasticity,Expand
Regulation of adult hippocampal neurogenesis - implications for novel theories of major depression.
TLDR
In this review, the potential role of adult hippocampusal neurogenesis and of neuronal stem or progenitor cells in depression is discussed with regard to those aspects that are brought up by recent research on how adult hippocampal Neurogenesis is regulated. Expand
Neural plasticity to stress and antidepressant treatment
Adaptations at the cellular and molecular levels in response to stress and antidepressant treatment could represent a form of neural plasticity that contributes to the pathophysiology and treatmentExpand
Signaling: cellular insights into the pathophysiology of bipolar disorder
TLDR
This experimental strategy provides data derived from the physiologic response of the system in affected individuals and addresses the critical dynamic interaction with pharmacologic agents that effectively modify the clinical expression of the pathophysiology. Expand
...
1
2
3
4
5
...